These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 29864093)

  • 1. Predictors of Resectability and Survival in Patients with Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment with FOLFIRINOX.
    Hu HJ; Li FY
    Ann Surg; 2018 Dec; 268(6):e95-e96. PubMed ID: 29864093
    [No Abstract]   [Full Text] [Related]  

  • 2. Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: An intention to treat analysis.
    Barenboim A; Lahat G; Geva R; Nachmany I; Nakache R; Goykhman Y; Brazowski E; Rosen G; Isakov O; Wolf I; Klausner JM; Lubezky N
    Eur J Surg Oncol; 2018 Oct; 44(10):1619-1623. PubMed ID: 30146251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resectability After First-Line FOLFIRINOX in Initially Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Experience.
    Nitsche U; Wenzel P; Siveke JT; Braren R; Holzapfel K; Schlitter AM; Stöß C; Kong B; Esposito I; Erkan M; Michalski CW; Friess H; Kleeff J
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1212-20. PubMed ID: 26350368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Added value of intra-operative ultrasound to determine the resectability of locally advanced pancreatic cancer following FOLFIRINOX chemotherapy (IMAGE): a prospective multicenter study.
    van Veldhuisen E; Walma MS; van Rijssen LB; Busch OR; Bruijnen RCG; van Delden OM; Mohammad NH; de Hingh IH; Yo LS; van Laarhoven HW; van Leeuwen MS; Nio CY; van Santvoort HC; de Vries J; Wessels FJ; Wilmink JW; Molenaar IQ; Besselink MG; van Lienden KP;
    HPB (Oxford); 2019 Oct; 21(10):1385-1392. PubMed ID: 31010633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FOLFIRINOX-based neoadjuvant therapy in borderline resectable or unresectable pancreatic cancer: a meta-analytical review of published studies.
    Petrelli F; Coinu A; Borgonovo K; Cabiddu M; Ghilardi M; Lonati V; Aitini E; Barni S;
    Pancreas; 2015 May; 44(4):515-21. PubMed ID: 25872127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy.
    Addeo P; Rosso E; Fuchshuber P; Oussoultzoglou E; De Blasi V; Simone G; Belletier C; Dufour P; Bachellier P
    Oncology; 2015; 89(1):37-46. PubMed ID: 25766660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A case of metastatic pancreatic adenocarcinoma with prolonged survival after combination of neoadjuvant FOLFIRINOX therapy and synchronous distal pancreatectomy and hepatectomy.
    Neofytou K; Giakoustidis A; Smyth EC; Cunningham D; Mudan S
    J Surg Oncol; 2015 May; 111(6):768-70. PubMed ID: 25556724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unresectable locally advanced pancreatic cancer: treatment with neoadjuvant leucovorin, fluorouracil, irinotecan, and oxaliplatin and assessment of surgical resectability.
    Mondo EL; Noel MS; Katz AW; Schoeniger LO; Hezel AF
    J Clin Oncol; 2013 Jan; 31(3):e37-9. PubMed ID: 23233707
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical Characteristics of Patients Experiencing Pathologic Complete Response Following Neoadjuvant Therapy for Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma.
    Hashemi-Sadraei N; Gbolahan OB; Salfity H; O'Neil B; House MG; Shahda S
    Am J Clin Oncol; 2018 Oct; 41(10):982-985. PubMed ID: 28968257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic Review of Resection Rates and Clinical Outcomes After FOLFIRINOX-Based Treatment in Patients with Locally Advanced Pancreatic Cancer.
    Rombouts SJ; Walma MS; Vogel JA; van Rijssen LB; Wilmink JW; Mohammad NH; van Santvoort HC; Molenaar IQ; Besselink MG
    Ann Surg Oncol; 2016 Dec; 23(13):4352-4360. PubMed ID: 27370653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Localized Pancreatic Cancer: Multidisciplinary Management.
    Coveler AL; Herman JM; Simeone DM; Chiorean EG
    Am Soc Clin Oncol Educ Book; 2016; 35():e217-26. PubMed ID: 27249726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study.
    Heinrich S; Besselink M; Moehler M; van Laethem JL; Ducreux M; Grimminger P; Mittler J; Lang H; Lutz MP; Lesurtel M;
    BMC Cancer; 2019 Jul; 19(1):675. PubMed ID: 31288786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: Is radiation necessary in the modern era of chemotherapy?
    Kim SS; Nakakura EK; Wang ZJ; Kim GE; Corvera CU; Harris HW; Kirkwood KS; Hirose R; Tempero MA; Ko AH
    J Surg Oncol; 2016 Oct; 114(5):587-596. PubMed ID: 27444658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complete pathological response following neoadjuvant FOLFIRINOX in borderline resectable pancreatic cancer - a case report and review.
    Gostimir M; Bennett S; Moyana T; Sekhon H; Martel G
    BMC Cancer; 2016 Oct; 16(1):786. PubMed ID: 27724927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FOLFIRINOX: from the ACCORD study to 2014.
    Oikonomopoulos GM; Syrigos KN; Skoura E; Saif MW
    JOP; 2014 Mar; 15(2):103-5. PubMed ID: 24618428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Progress in neoadjuvant and transformation therapy of pancreatic cancer].
    Hu DD; Dai MH
    Zhonghua Wai Ke Za Zhi; 2017 Jan; 55(1):69-72. PubMed ID: 28056259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. "Radiological and Surgical Implications of Neoadjuvant Treatment With FOLFIRINOX for Locally Advanced and Borderline Resectable Pancreatic Cancer.".
    Godhi SA; Parasar K; Saluja S; Mishra P
    Ann Surg; 2017 Jun; 265(6):E73. PubMed ID: 28486290
    [No Abstract]   [Full Text] [Related]  

  • 18. [The value of extended surgery for pancreatic cancer in the context of neoadjuvant therapy].
    Zhang TP; Liu YZ; Cao Z
    Zhonghua Wai Ke Za Zhi; 2020 Jul; 58(7):481-485. PubMed ID: 32610414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.
    Rose JB; Rocha FG; Alseidi A; Biehl T; Moonka R; Ryan JA; Lin B; Picozzi V; Helton S
    Ann Surg Oncol; 2014 May; 21(5):1530-7. PubMed ID: 24473642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complete pathological response after FOLFIRINOX for locally advanced pancreatic cancer. The beginning of a new era? Case report and review of the literature.
    Valeri S; Borzomati D; Nappo G; Perrone G; Santini D; Coppola R
    Pancreatology; 2014; 14(5):425-30. PubMed ID: 25278312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.